Document is current

Article History

Accepted: 19 July 2023

First Online: 14 September 2023

Declarations

:

: Funding for medical writing and editorial support in the preparation of this manuscript was provided by Sumitomo Pharma America, Inc. (formerly Urovant Sciences, Inc.; Marlborough, MA, USA).

: AB has consulted for AstraZeneca and serves as a geriatrics content consultant for Wolters Kluwer. NT and HD have nothing to disclose. NB is a consultant for Institute for Healthcare Improvement (Faculty), is section editor for SLACK, Inc., and is an author of the American Geriatrics Society Beers Criteria^® for Potentially Inappropriate Medication Use in Older Adults. JA is a consultant pharmacist with Medication Managers and a Clinical Pharmacist, Pharmacy Corporate Development, with Brookshire Grocery Company. RGS is an advisor for Sumitomo Pharma America.

: Data sharing is not applicable to this article as no datasets were generated or analyzed.

: Not applicable.

: The first draft of this manuscript was written by a medical writer under the direction of the authors. All authors participated in the review and interpretation of literature and relevant data, critically revised the work for intellectual content, and read and approved the final version for publication.